Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06820034 · ClinicalTrials.gov registry record · Phase 2

Empowering Cessation ACS South Region

A Phase 2 study, sponsored by University of Oklahoma.

Recruiting
Registry status
Phase 2
Development phase
400
Enrollment target

NCT06820034: Recruiting Phase 2 study, sponsored by University of Oklahoma.

NCT06820034 is a Phase 2 study that is actively recruiting participants, run by University of Oklahoma. The registered enrollment target is 400 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (201% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06820034, a Phase 2 study, is actively recruiting participants, sponsored by University of Oklahoma.

RECRUITING
Registry status
Phase 2
Development phase
400 participants
Enrollment target

Study Summary

Sexual and/or gender minority (SGM) people face a disproportionate burden of cancer risk, and tobacco use is a key modifiable risk factor. SGM tobacco-related disparities are especially pronounced in places with high levels of stigma against SGM people. This community-engaged and remotely-delivered Research Scholar Grant project will evaluate an empowerment-based smoking cessation intervention tailored for SGM people in high-stigma places. In partnership with Freedom Oklahoma (OK) and a Community Advisory Board from Arkansas (AR) and Texas (TX) this projects aims to: (1) Adapt SGM-serving volunteer activities from the Oklahoma intervention pilot study for delivery in nearby states; (2) Test intervention efficacy among SGM adults in OK, AR, and TX; (3) Identify treatment mechanisms.

Primary Outcome

Self-reported smoking cessation abstinence will be biochemically verified with the iCOQuit Smokerlyzer expired carbon monoxide device 26 weeks after the participant's quit smoking date.

Interventions

  • OTHER Empowering Cessation for the ACS South

Trial Details

FieldValue
Enrollment Target 400 participants
Start Date 2025-08-14
Est. Completion 2028-12-31
Phase Phase 2
University of Oklahoma

358 total trials

What NCT06820034 shows while recruiting

NCT06820034 is an interventional study that assigns participants to a tested intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (201% higher).

The record links to 0 conditions, and to 1 intervention - of which Empowering Cessation for the ACS South is the first listed.

NCT06820034 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT06820034 about?

NCT06820034 is a clinical study titled "Empowering Cessation ACS South Region". Sexual and/or gender minority (SGM) people face a disproportionate burden of cancer risk, and tobacco use is a key modifiable risk factor. SGM tobacco-related disparities are especially pronounced in places with high levels of stigma against SGM people. This community-engaged and remotely-delivered ...

What is the current status of trial NCT06820034?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 400 participants. The study started on 2025-08-14. Estimated completion is 2028-12-31.

What interventions are being tested in trial NCT06820034?

The interventions under investigation include: Empowering Cessation for the ACS South (OTHER).

Who is sponsoring clinical trial NCT06820034?

This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT06820034's enrollment target sits among peer trials

400 96th of 2000 higher than 1,898 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01665326 · 400 participants

    Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease

  • NCT02108054 · 400 participants · NA

    Behavioral and Functional Task Development, Implementation, and Testing

  • NCT02216500 · 400 participants · NA

    Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy

  • NCT02250352 · 400 participants

    Core Biopsies for Establishing a Breast Tumor Tissue Repository

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06820034, the US trial registry maintained by the National Library of Medicine. NCT06820034 (mid enrollment · none site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.